Promising Results for GLP-1 Receptor Agonists in Reducing Chronic Migraine Frequency

Migraines affect approximately 15% of people worldwide, often leading to significant discomfort and disruption in daily life. While multiple treatments are available, some individuals do not find relief, or they experience adverse side effects that limit their options. Recent research introduces a novel approach using medications known as GLP-1 receptor agonists—drugs typically used for weight loss and diabetes management—as potential migraine therapeutics.

A pilot study conducted by Italian researcher Simone Braca and colleagues explored the effects of liraglutide, a GLP-1 receptor agonist, on individuals suffering from chronic migraines coupled with obesity. Over a 12-week period, 31 participants (mostly female) received liraglutide and documented their headache frequency. The findings revealed a substantial decrease in migraine days—reducing from an average of about 20 days per month to 11 days after treatment.

Approximately half of the participants experienced a 50% reduction in migraine frequency, with some showing even higher improvements—seven individuals saw up to a 75% decrease, and one participant became migraine-free. Mild gastrointestinal side effects such as nausea and constipation were reported but resolved without impacting the study.

Interestingly, the study indicated that weight loss was not the primary factor behind the migraine relief, as participants’ BMI remained largely unchanged. The researchers hypothesize that liraglutide may influence intracranial pressure (ICP), a known factor in migraine severity, although direct measurements were not taken in the study. Future research aims to clarify the mechanism at play.

This pioneering research opens new avenues for treating chronic migraines, especially in cases resistant to traditional therapies. While more extensive studies are necessary, these early results suggest that GLP-1 receptor agonists like liraglutide could become valuable tools in managing this debilitating condition.

source: https://medicalxpress.com/news/2025-07-ozempic-drug-significantly-frequency-chronic.html